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SUMMARY
The involvement of Toll-like receptor 4 (TLR4) in immunity against human herpesviruses has not
been previously demonstrated. We show that infection of endothelial cells with Kaposi sarcoma
herpesvirus (KSHV), a human oncogenic virus, leads to rapid suppression of TLR4 expression.
This is a mechanism of immune escape as TLR4 mediates innate immunity against KSHV. In
vitro, cells lacking TLR4 are more susceptible to KSHV infection, whereas activation of TLR4
protects cells from infection. In vivo, HIV-1-infected individuals carrying a mutant TLR4 allele
appear more likely to have multicentric Castleman's disease, a lymphoproliferation associated with
enhanced KSHV replication. ERK activation by KSHV structural proteins and the KSHV-encoded
vGPCR plays a key role in the TLR4 downregulation, whereas the KSHV vIRF1 also contributes
to this effect. Our findings reveal a role for TLR4 in innate immunity against herpesviruses and
suggest the potential use of TLR4 agonists for the treatment of KSHV-related neoplasms.
INTRODUCTION
Toll-like receptors (TLR) are a family of membrane pattern recognition receptors
recognizing highly conserved metabolic products of invading pathogens, termed pathogen-
associated molecular patterns (PAMPs). TLRs are type I glycoproteins consisting of an
extracellular PAMP recognition domain and a cytoplasmic Toll/interleukin-1 receptor
homology signaling domain. Effective pathogen recognition can be achieved through a
small number of TLRs (ten in humans). As PAMPs are indispensable for the invading
pathogen, no escape mutants can evolve. Upon PAMP recognition, TLR activation leads to
the initiation of an innate inflammatory response through activation of the nuclear factor κB
(NF-κB), mitogen-activated protein kinase (MAPK), and interferon regulatory factor (IRF)
pathways (Akira et al., 2006; Janeway and Medzhitov, 2002). In parallel, a complex
regulatory network of TLR signaling exists to regulate this innate response (Liew et al.,
2005).
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The first characterized mammalian TLR was the human TLR4 (Medzhitov et al., 1997). It is
expressed by cells of the immune system, such as dendritic cells, macrophages, and B
lymphocytes, but also by endothelial cells. TLR4 acts in combination with serum or
membrane CD14 and the adaptor protein MD2 as the receptor of bacterial
lipopolysaccharide (LPS), playing a key role in innate responses against Gram-negative
bacteria (Akira et al., 2006). TLR4 also recognizes other ligands such as the glycoprotein F
of respiratory syncytia virus (RSV) (Kurt-Jones et al., 2000), as well as endogenous proteins
including heat shock proteins, fibrinogen, and high-mobility-group box 1 (Apetoh et al.,
2007; Marshak-Rothstein, 2006). Based on its exogenous ligands, TLR4 is generally
associated with responses to Gram-negative bacteria and RSV. Notably, two single
nucleotide polymorphisms (SNP) in the human TLR4 gene (Asp299Gly resulting from an
A/G substitution, rs4986790, and Ile399Thr resulting from a C/T substitution, rs4986791)
have been associated with severity of RSV-associated bronchiolitis and Gram-negative
sepsis (Schroder and Schumann, 2005). Activation of TLR4 by a mouse RNA virus (mouse
mammary tumor virus; MMTV) is thought to lead to subversion of the immune response
(Burzyn et al., 2004). Furthermore, TLR4 has been implicated in responses against hepatitis
C virus (Machida et al., 2006) and in mouse models of hepatitis B virus infection (Isogawa
et al., 2005), whereas TLR4 activation by LPS in mouse macrophages inhibits replication of
murine herpesvirus 68 (MHV68) by induction of an IRF3- and IRF7-mediated response
(Doyle et al., 2002). However, a role for TLR4 in responses against human herpesviruses
has not previously been demonstrated.
Kaposi sarcoma-associated herpesvirus (KSHV; also known as human herpesvirus 8) is an
oncogenic human γ-herpesvirus associated with the development of Kaposi sarcoma (KS), a
neoplasm of lymphatic endothelial-type cells (Wang et al., 2004), and certain
lymphoproliferations, such as multicentric Castleman's disease (MCD) (Boshoff and Weiss,
2002). As a herpesvirus, KSHV establishes life-long infection in its host. In latently infected
cells, only a fraction of viral genes are expressed, maintaining the viral episome, and
providing a proliferative and immune escape advantage to infected cells. The viral genes
expressed during latency include the latency-associated nuclear antigen 1 (LANA-1), viral
cyclin, and viral FLICE inhibitory protein (vFLIP; reviewed in Moore and Chang [2003]).
When infected cells enter a productive (lytic) program of gene expression, most of the viral
genes are expressed, virions are formed, and new cells are recruited to be infected. Lytic
KSHV genes include the viral G protein-coupled receptor (vGPCR), which is a
multifunctional viral oncogene homologous to the human IL8 receptor, and the viral IRF1
(vIRF1), which inhibits interferon signaling (reviewed in Cannon [2007] and Moore and
Chang [2003]). As herpesviruses have evolved to establish persistent infection (and
therefore an immunological equilibrium with their host), most of the viral mechanisms of
immune evasion occur during lytic and primary infection (Coscoy, 2007; Moore and Chang,
2003). This equilibrium is disturbed in immunosuppressed individuals, resulting in
uncontrolled proliferation of infected cells and occasional development of cancer. Thus, the
incidence of KSHV-related malignancies is dramatically increased among transplant
recipients during iatrogenic immunosuppression and in HIV-1-infected individuals, where
KS is the most common AIDS-related cancer (Boshoff and Weiss, 2002).
Although several aspects of the KSHV-specific immune responses and viral mechanisms of
immune escape have been studied (Coscoy, 2007), the role and regulation of TLRs in innate
immunity against KSHV remain unknown. Here we show that TLR4 mRNA levels and
protein expression are significantly downregulated upon primary KSHV infection of human
lymphatic endothelial cells (LEC). Using macrophages from TLR4-knockout mice, siRNA-
mediated silencing of TLR4 in human LEC, and activation of endogenous TLR4 signaling,
we demonstrate that TLR4 mediates an innate immune response against KSHV. The in vivo
relevance of these findings is demonstrated by the higher incidence of the Asp299Gly TLR4
Lagos et al. Page 2
Cell Host Microbe. Author manuscript; available in PMC 2009 June 18.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
SNP among HIV-1-infected individuals with MCD, a KSHV-driven lymphoproliferation
associated with high KSHV load. Consistently, primary LEC carrying this TLR4 allele are
more susceptible to KSHV infection than LEC carrying the wild-type TLR4 gene.
Furthermore, we demonstrate that KSHV suppresses TLR4 through activation of the
extracellular signal-regulated kinase (ERK) MAPK pathway during viral binding (viral gene
expression-independent mechanism), and by way of vIRF1 and ERK activation by vGPCR
(viral gene expression-dependent mechanism).
RESULTS
KSHV Infection of Lymphatic Endothelial Cells Leads to Suppression of TLR4 Expression
We have previously determined the immune transcriptional signature of KSHV-infected
LEC (KLEC) using gene expression microarray (GEM) profiling (Lagos et al., 2007). We
analyzed these data focusing on TLRs and observed a significant downregulation of TLR4
levels (false discovery rate threshold q < 0.005; Figure 1A). The only other significant
effects of infection on TLR expression were an upregulation of TLR2 and a downregulation
of TLR3. However, the normalized signal for basal TLR3 mRNA levels in LEC was low
(Figure S1A), suggesting that TLR3 is not significantly expressed in these cells. Thus, we
considered only TLR4 as significantly downregulated after infection. TLR4 acts as the
functional LPS receptor, in the presence of soluble CD14 (sCD14), on dermal
microvasculature, umbilical vein, and lymphatic endothelial cells (Faure et al., 2000; Pegu et
al., 2008; Pugin et al., 1993). In our system, we confirmed that TLR4 is expressed and
functional in response to LPS (through upregulation of ICAM-1) in primary LEC (Figures
S1B and S1C). Following this, we validated our GEM data by quantitative reverse
transcriptase polymerase chain reaction (qRTPCR) and confirmed that TLR4 mRNA levels
are downregulated after KSHV infection, whereas mRNA levels of TLR9, the TLR typically
associated with responses to DNA viruses (Guggemoos et al., 2008; Muller et al., 2008),
were not affected by KSHV (Figure 1B). The TLR4 mRNA decrease led to significant
downregulation of TLR4 surface expression (reducing TLR4 geomean fluorescence to levels
similar to isotype control; Figures 1C and S1D). Notably, TLR4 mRNA levels were
downregulated as early as 6 hr postinfection (p.i.) and the effect persisted up to 72 hr p.i.
(Figure 1D). Early TLR4 downregulation (6 hr p.i.) also occurred when LEC were exposed
to UV-inactivated KSHV (Figure 1E) inferring that structural KSHV proteins contribute to
this effect. However, at later time points (72 hr p.i.), TLR4 levels significantly increased in
LEC exposed to UV-inactivated KSHV compared to KLEC (Figure 1E). Furthermore, TLR4
downregulation correlated with number of KSHV-infected cells (Figure 1F). These findings
indicated that KSHV employed mechanisms independent of and driven by viral gene
expression to downregulate TLR4. To exclude any confounding effects of contaminating
traces of LPS on TLR4 expression, we showed that LPS did not affect basal TLR4
expression in LEC (Figure S1E) and that the TLR4 downregulation still occurred when the
infection was performed in the presence of polymyxin-B (an inhibitor of the LPS-TLR4
interaction; Figure S1F).
Next we assessed the functional relevance of the TLR4 downregulation by KSHV. One of
the first events upon TLR4 activation involves the phosphorylation, ubiquitination, and
degradation of IRAK1 (Gottipati et al., 2008). In LEC, we observed transient
phosphorylation of IRAK1 within 5–10 min of stimulation with LPS followed by protein
degradation. IRAK1 activation after LPS stimulation was significantly impaired in KLEC
(72 hr p.i.; Figure 1G). Similarly, transcriptional induction and secretion of TNF-α after
stimulation with LPS (one of the endpoints of the TLR4 signaling cascade) was significantly
impaired in KLEC (72 hr p.i.; Figure 1H).
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TLR4 Mediates an Innate Immune Response Against KSHV
The rapid TLR4 downregulation during primary KSHV infection of LEC suggested that
TLR4 might play a role in the innate response against this virus. Although KSHV does not
infect mice with functional T lymphocytes, it has been shown using NOD/SCID mice that
macrophages are one of the viral cellular targets in vivo (Parsons et al., 2006). Therefore, we
first tested the role of TLR4 in the response against KSHV using peritoneal macrophages
from C57BL10/ScNJ mice, which lack the Tlr4 gene, and wild-type controls (C57BL10/
ScSnJ). KSHV infection of macrophages from the Tlr4 knockout mice led to a 2- to 3-fold
higher viral gene expression compared to wild-type controls (Figure 2A).
As differences in the activation of mouse and human TLR4 genes have been reported
(Kawasaki et al., 2001) and KSHV is considered to be species restricted, we next tested the
role of TLR4 in the innate response during primary infection of human LEC. Similar to the
data we obtained using macrophages from Tlr4 knockout mice, infection of human LEC
after siRNA-mediated TLR4 silencing resulted in higher viral gene expression (Figure 2B).
This correlated with an impaired innate response as siRNA-mediated TLR4 silencing also
caused impaired induction of TNF-α, IL1-β, IL-6, and IFN-β after KSHV infection of LEC
(Figure 2C). Together, these results demonstrated that TLR4 contributes to the innate
response during primary KSHV infection. This antiviral activity is likely to be the result of
TLR4 activation by a viral envelope glycoprotein, as exposure of LEC to UV-inactivated
KSHV also led to a TLR4-dependent induction of TNF-α, IL1-β, IL-6, and IFN-β (Figure
2D).
Next, we investigated whether it was possible to inhibit KSHV infection by activating TLR4
before exposure to the virus. Activation of TLR4 signaling with LPS resulted in decreased
number of infected cells (Figure 3A), a reduction in the number of viral genome copies per
infected cell (Figure 3B), and lower latent, early lytic, and late lytic viral gene expression
(Figure 3C). To exclude nonspecific effects of LPS on KSHV infection, we showed that
LPS treatment did not affect KSHV infection of macrophages from C57BL10/ScNJ Tlr4−/−
mice or human 293T cells (Figure S2), which do not express TLR4 and do not respond to
LPS. Furthermore, we showed that TLR4 activation by LPS resulted in IFN-β induction
(Figure 3D), and that inhibition of type I interferon activity reversed the protective effect of
TLR4 activation against KSHV infection (Figure 3E).
Increased Incidence of the Asp299Gly TLR4 SNP among HIV-1-Infected Individuals with
MCD
Based on the above results we investigated whether SNPs associated with the deregulation
of TLR4 activity (Ferwerda et al., 2007; Tulic et al., 2007) result in higher KSHV load in
vitro and in vivo and therefore development of KSHV-associated neoplasms. First, we
compared primary human LEC carrying a heterozygous Asp299Gly mutant allele with wild-
type TLR4 LEC. In agreement with previous observations with transfected wild-type and
mutant TLR4 constructs (Tulic et al., 2007), we observed that LEC-TLR4A/A (wild-type)
express higher levels of surface TLR4 than LEC-TLR4A/G (mutant), whereas TLR4 mRNA
levels did not differ between the two cell types. The two cell types were also matched for
TLR9 mRNA levels (Figure 4A). To determine the TLR4 activity in the wild-type and
mutant cells, we examined their response to LPS stimulation. In agreement with previous
findings, we observed that stimulation of LEC-TLR4A/G with LPS resulted in significantly
higher induction of proinflammatory cytokine transcription compared to wild-type LEC.
Notably, in contrast to the inflammatory gene profile, our data also suggested that LEC-
TLR4A/G produced less IFN-β upon TLR4 stimulation with LPS (Figure 4B). As we showed
that KSHV activates TLR4 (Figure 2B), we speculated that the combination of an impaired
interferon and an enhanced inflammatory TLR4-mediated response could make the mutant
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cells more susceptible to KSHV infection. Indeed, we showed that KSHV infection of LEC-
TLRA/G was significantly more efficient compared to LEC-TLR4A/A (Figures 4C and 4D).
The above results indicated that cells carrying TLR4 SNP may be more susceptible to
KSHV infection. To assess this hypothesis in vivo, we determined the frequency of two
TLR4 SNPs in a cohort of 109 HIV-1-infected individuals. In this cohort, 43 individuals
were diagnosed with KSHV-associated cancers (23 KS, 9 KS and MCD, 11 MCD), and 66
HIV-1-infected controls had non-KSHV-associated cancers or no cancer (Table S1). The
frequencies of the Asp299Gly and Ile399Thr polymorphisms in the entire cohort were
12.8% and 4.6%, respectively. All individuals were heterozygous for the polymorphisms
and the Ile399Thr SNP cosegregated with the Asp299Gly mutation (Figure 5A). We
observed a statistically significant higher frequency of the Asp299Gly SNP among
individuals with MCD in comparison with non-KSHV cancer controls (30% versus 10.6%, p
= 0.044; Figures 5A and 5B) and in comparison to individuals with only KS (30% versus
4.3%, p = 0.026). Furthermore, our data showed that HIV-1-infected individuals with the
Asp299Gly SNP were more likely to have MCD when compared to individuals carrying the
wild-type TLR4 allele (odds ratio 4.34, 95% confidence interval 1.3–14.4, p = 0.021). We
also confirmed in this cohort that MCD (with or without KS) is associated with higher
plasma KSHV load compared to KS (Figure 5C; KSHV load is shown at time of diagnosis).
These findings infer that HIV-1/KSHV-co-infected individuals with the Asp299Gly TLR4
SNP are more likely to have MCD and are consistent with our in vitro results demonstrating
the role of TLR4 in immunity against KSHV.
vGPCR and vIRF1 Contribute to the TLR4 Downregulation by KSHV
We have shown here that TLR4 mediates an antiviral response and is significantly
downregulated upon KSHV infection. We therefore investigated the mechanism employed
by KSHV to suppress TLR4. We determined TLR4 expression in LEC expressing 25
individual KSHV genes using a lentiviral gene delivery vector as previously reported (Lagos
et al., 2007; Vart et al., 2007) to achieve efficient and stable viral gene expression in LEC.
An initial screen revealed that expression of the KSHV vGPCR or vIRF1 caused a decrease
in TLR4 mRNA levels, whereas no viral genes resulted in significant upregulation of TLR4
(Table S2). These findings were first confirmed for vIRF1 at the mRNA and protein levels
(Figures 6A and S3), showing a decrease of TLR4 expression by vIRF1 in a dose-dependent
manner. Furthermore, we showed that vIRF1 is primarily responsible for the TLR4
downregulation, but also that vGPCR contributes to suppression of TLR4 expression as
coexpression of vIRF1 and vGPCR in LEC led to an additive effect on TLR4 expression
(Figure 6B). In these experiments, the viral genes were expressed at levels where no
cytopathic effects were observed (a maximum of 10 copies/cell for vGPCR, 50 copies/cell
for vIRF1 when expressed alone, and 20 copies/cell when expressed with vGPCR). Notably,
at these expression levels, vIRF1 and vGPCR resulted in a decrease in TLR4 protein
expression comparable to that observed in KLEC (72 hr p.i.), although the TLR4 mRNA
downregulation was more pronounced in KLEC (Figures 1B, 1C, and 6B). We have
previously shown that both vIRF1 and vGPCR are expressed in KLEC at 72 hr p.i. (Lagos et
al., 2007; Vart et al., 2007).
To confirm that the TLR4 downregulation by vIRF1 and vGPCR was functionally relevant,
we tested whether these genes affected response to LPS stimulation in LEC. We found that
similar to KLEC, LEC expressing vIRF1 and vGPCR displayed impaired TNF-α induction
after TLR4 activation, whereas response to TLR9 stimulation was similar between these
cells and controls (Figure 6C), excluding that the observed hyporesponsiveness to LPS was
due to inhibition of TLR signaling by these viral genes at a different level downstream of
TLR4.
Lagos et al. Page 5
Cell Host Microbe. Author manuscript; available in PMC 2009 June 18.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
The Role of the ERK/MAPK Pathway in TLR4 Regulation by KSHV in Endothelial Cells
The KSHV-encoded vIRF1 has been shown to inhibit IRF-driven transcription (Coscoy,
2007; Moore and Chang, 2003), whereas basal human TLR4 expression is regulated by
interferon consensus-binding protein (ICSBP) (Rehli et al., 2000), which is the IRF with the
highest sequence similarity to vIRF1. On the other hand, vGPCR activates several signaling
pathways (reviewed in Cannon [2007]), none of which are directly associated with negative
regulation of TLR4. We therefore investigated the mechanism by which vGPCR causes
suppression of TLR4 expression. This was addressed by determining TLR4 expression after
treating vGPCR-expressing LEC with chemical inhibitors of pathways that are activated by
this gene, such as the NF-κB, phosphatidylinositol-3-kinase (PI3K), ERK and Jun N-
terminal kinase (JNK) MAPK pathways, or those involved in TLR4 expression in other cell
types, such as the p38/MAPK pathway. We found that only inhibitors of ERK
phosphorylation were able to completely reverse the observed TLR4 downregulation (Figure
7A) in a dose-dependent manner (Figure 7B). To exclude any nonspecific effects of the
synthetic inhibitors we also showed that siRNA-mediated silencing of ERK1 and ERK2
reversed the vGPCR-mediated TLR4 suppression (Figure 7C), without affecting expression
of vGPCR (Figure S4A).
Next, we confirmed that ERK was phosphorylated in KLEC and showed that inhibition of
ERK activation partly restored TLR4 levels in KSHV-infected LEC (72 hr p.i.; Figure 7D).
Although it has been shown that inhibition of ERK activation before KSHV infection
inhibits viral gene expression (Sharma-Walia et al., 2005), treatment of KLEC (72 hr p.i.)
with ERK-phosphorylation inhibitors did not affect viral gene expression (Figure S4B).
Inhibitors of PI3K, JNK, and p38 activation did not affect the KSHV-induced TLR4
downregulation, showing that the effect of ERK-phosphorylation inhibitors was not due to
nonspecific inhibition of other kinases. These findings were consistent with a contribution of
vGPCR to the observed TLR4 downregulation. The contribution of the NF-κB pathway to
TLR4 downregulation in KLEC was excluded, as NF-κB inhibitors did not affect the
vGPCR-mediated TLR4 downregulation, and vFLIP, the other major viral activator of NF-
κB, did not affect TLR4 expression (Table S2).
Following this, we tested the effect of ERK activation inhibitors in the early TLR4
regulation by KSHV (6 hr p.i.), as it has been shown that ERK activation is also caused by
viral binding on the surface of endothelial cells (Sharma-Walia et al., 2005). ERK
phosphorylation inhibitors and siRNA-mediated silencing of ERK1 and ERK2 prior to
infection reversed early TLR4 suppression in KLEC (6 hr p.i.; Figure 7D). Another possible
mechanism of TLR4 downregulation in endothelial cells during early stages of infection,
mediated by induction of reactive oxygen species (Ishida et al., 2002), did not affect TLR4
expression in KLEC. Inhibitors of ERK activation did not affect TLR9 mRNA levels in
KLEC (Figure S4C). This apparent specific effect of ERK activation on TLR4 in LEC could
be explained by the fact that conserved ETS binding sites are present in the TLR4 promoter,
whereas the human TLR9 promoter does not include any ETS (conserved or nonconserved)
sites (Figure S4D). Together, these data showed that ERK phosphorylation due to viral
binding mediates TLR4 suppression during the early stages of KSHV infection, whereas
ERK phosphorylation by vGPCR also contributes to TLR4 downregulation at 72 hr p.i.
DISCUSSION
Understanding the mechanisms of the host immune response against viral infections and the
strategies employed by viruses to escape this response is crucial for designing new therapies
for infectious diseases. In the case of cancers caused by oncogenic viruses, such as KSHV,
current treatment regimes rely on systemic cytotoxic therapy and immune system
reconstitution through antiretroviral therapy (ART), but take little advantage of our current
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knowledge of KSHV immunobiology (Hansen et al., 2007). In this respect, revealing the
role and mechanisms of regulation of the TLR-mediated response to KSHV is essential, as
clinically approved agonists and antagonists of several TLRs are available (Kanzler et al.,
2007). In this study, we define a particular TLR (TLR4), which mediates an innate response
against KSHV. To our knowledge, this is the first report that implicates TLR4 in immune
responses against human herpesviruses.
TLR4 mediates antiviral immunity through induction of an interferon antiviral gene
expression program and production of inflammatory cytokines. Its antiviral activity has been
demonstrated mainly against RNA viruses such as RSV and hepatitis C virus (Kurt-Jones et
al., 2000; Machida et al., 2006). We extend the antiviral role of TLR4 to the family of
human herpesviruses by demonstrating that cells with reduced (siRNA silencing) or no
(knockout mice) TLR4 expression display an impaired immune response during primary
KSHV infection and increased viral gene expression (Figure 2). Our findings also suggest
that this antiviral activity is due to direct binding between TLR4 and a KSHV envelope
glycoprotein, such as glycoprotein B or K8.1 (Figure 2). Importantly, although our data were
obtained using endothelial cells, it is likely that TLR4 also plays a role in innate immunity
during KSHV infection of B lymphocytes as these cells express functional TLR4, and they
are responsive to TLR4 ligands (Peng, 2005).
The only other virus, which has been shown to induce innate immunity by direct interaction
with TLR4 is RSV (Kurt-Jones et al., 2000). In the context of RSV infection, the Asp299Gly
and Ile399Thr TLR4 mutations have been associated with severity of RSV-induced
bronchiolitis (Tal et al., 2004). It has been suggested that these mutations affect TLR4
function by impairing transport of the receptor to the cell membrane (Tulic et al., 2007) and
that the Asp299Gly SNP is associated with a proinflammatory phenotype (Ferwerda et al.,
2007). In our study we observed that LEC heterozygous for the Asp299Gly mutation are
more susceptible to KSHV infection (Figure 4), and we show an association of the
Asp299Gly SNP among HIV-1-infected individuals with MCD (Figure 5), a
lymphoproliferation associated with high KSHV load (Boivin et al., 2002; Oksenhendler et
al., 2000). Interestingly, our data suggest that this association with MCD may be due to a
combination of the impaired interferon response and a proinflammatory phenotype of cells
carrying the Asp299Gly allele. Such a proinflammatory environment is strongly associated
with increased KSHV gene expression during primary KSHV infection in vitro (Sadagopan
et al., 2007) and specifically MCD development in vivo (Oksenhendler et al., 2000). Further
larger prospective studies should evaluate these findings and the association of these SNPs
with KSHV-associated malignancies in other geographical and/or HIV-1-negative cohorts.
However, the results presented here provide the first crucial insight into the role of TLR4 in
controlling KSHV infection in humans and identify the first genetic factor that could be
associated with MCD development.
Our results reveal KSHV as the first virus, which targets TLR4 expression as an immune
evasion mechanism. Interestingly, it has been reported that TLR4 is not expressed in the KS
biopsy-derived SLK endothelial cell line (Livengood et al., 2007). However, SLK cells have
no detectable KSHV episome or viral gene expression; therefore, the lack of TLR4
expression in this cell line is unlikely to be associated with KSHV. Moreover, TLR4 is a
mediator of an innate response, and its regulation by the virus should be rapid and occur
during primary infection and lytic replication when new cells are about to be infected.
Importantly, the maintenance of KSHV latency relies on this de novo infection of cells
(Grundhoff and Ganem, 2004). Consistent with the above, in our primary infection model
we observe a rapid and dramatic drop of TLR4 expression in infected endothelial cells
(Figure 1). Of note immune evasion mechanisms employed by herpesviruses have evolved
to delay immune responses allowing establishment of latency, rather than to completely
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escape immune surveillance. Thus, it is not surprising that cells lacking TLR4 are more
susceptible to infection by KSHV (Figure 2) despite the fact that KSHV has evolved
mechanisms to downregulate TLR4. Furthermore, we excluded the possibility that this early
downregulation is a result of the previously reported mRNA shutoff caused during the early
stages of infection (Glaunsinger and Ganem, 2004) by showing that TLR9 mRNA levels are
not affected by infection (Figure 1). We used TLR9 as control because it is the TLR
typically associated with responses to DNA viruses (Akira et al., 2006), including the related
murine gammaherpesvirus-68 (Guggemoos et al., 2008). Our data do not exclude that TLR9
could be regulated by KSHV at the posttranscriptional level.
We show that ERK activation due to the activity of vGPCR or KSHV structural proteins,
such as K8.1 or glycoprotein B (Sharma-Walia et al., 2005), plays a key role in the TLR4
downregulation in endothelial cells. Interestingly, it has been reported that in murine
dendritic cells ERK activation leads to TLR4 upregulation (An et al., 2002), which suggests
that TLR4 regulation is cell-type specific. Moreover, we speculate that TLR4 regulation
through ERK activation in KLEC may be part of a more complex signaling network
involving the simultaneous activation of other signaling cascades including crosstalk
between different arms of the MAPK signaling.
We identify two lytic KSHV genes, vIRF1 and vGPCR, that contribute to TLR4
transcriptional repression in endothelial cells. Our results demonstrate that vIRF1 and
vGPCR lead to TLR4 downregulation through two independent mechanisms. vIRF1 is a
known viral inhibitor of IRF-mediated transcription (Coscoy, 2007; Moore and Chang,
2003), with high homology to the cellular ICSBP, a transcription factor necessary for basal
TLR4 expression (Rehli et al., 2000). We have previously shown that there is background
IRF-mediated transcription in LEC even in the absence of interferon (Lagos et al., 2007),
which could explain the effect of vIRF1 on TLR4 transcription. On the other hand, we show
that vGPCR-mediated TLR4 suppression occurs by way of ERK activation (Figure 6). Of
note, among the three main MAPK pathways, p38 is mainly and positively associated with
TLR4 transcription, as the TLR4 gene has a PU.1 element in its promoter.
The driving force in the evolution of herpesviruses is the establishment of latency in the
host. This strongly depends on efficient escape from the immune system, mainly during
primary infection and lytic replication. Our data reveal that evasion of TLR4-mediated
response is one such target for KSHV, and we show that one of the mechanisms that the
virus employs to escape this response involves suppression of TLR4 expression. As we
show that TLR4 simulation impedes KSHV gene expression (Figure 3), our findings suggest
the potential of TLR4 agonists in KSHV-related neoplasm prevention or treatment.
Activation of TLR4 could boost antigen presentation (Kanzler et al., 2007) and potentiate
cytotoxic therapy (Apetoh et al., 2007), but also exert a direct antiviral effect. A future
clinical study could be to investigate whether activation of TLR4 signaling with synthetic
TLR4 agonists leads to reduced circulating KSHV load and therefore could be used for the
treatment of KSHV-related malignancies.
EXPERIMENTAL PROCEDURES
Animals and Cells
C57BL10/ScNJ (Jax mice number 003752) and C57BL10/ScSnJ mice (wild-type for the
Il12rβ gene; Jax mice number 000476) were purchased from Jackson Laboratory.
Thioglycollate-induced peritoneal macrophages were grown in Dulbecco's modified Eagle's
medium (GIBCO), supplemented with 10% FCS. LEC were grown as described (Lagos et
al., 2007). All experiments were performed before passage 5. TLR4 signaling in LEC was
activated with 1 μg/ml sCD14 and 100 ng/ml LPS for 6 hr. Under these conditions, LPS
Lagos et al. Page 8
Cell Host Microbe. Author manuscript; available in PMC 2009 June 18.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
treatment did not cause any apoptosis in LEC (tested with the MTT assay; not shown).
TLR9 signaling was activated by incubation of LEC with 5 μg/ml of CpG type A, B, and C
(ODN2336, ODN10103, ODN2395; Coley Pharma) for 16 hr. BCBL1-1C and 293T cells
were grown as previously described (Lagos et al., 2007).
KSHV Production and Infection of LEC
KSHV was produced and LEC were infected as previously described (Lagos et al., 2007).
KSHV was inactivated by UV irradiation for 30 min in a Stratalinker 2400 (Stratagene).
LANA mRNA (by qRTPCR) was undetectable in LEC treated with UV-inactivated KSHV
48 hr p.i. GFP expression in KLEC was used as a surrogate marker of infection and
infections typically resulted in 25%–40% GFP-expressing KLEC (72 hr p.i.). KSHV
infection of mouse macrophages was detected by qRTPCR.
GEM Analysis
GEM profiles of six pairs of LEC and KLEC (3 days p.i.) were obtained and analyzed as
described (Lagos et al., 2007), using Affymetrix hg-u133+2 GeneChips. The GEM data are
available in the ArrayExpress database (accession number E-MEXP-561).
Antibodies
Surface expression of proteins was assessed by flow cytometry (FACSCalibur, Becton
Dickinson). We used RPE labeled antibodies against human TLR4 (Santa Cruz), ICAM1
(PharMingen), and the corresponding isotype controls. Analyses were done after gating live
cells. The levels of ERK activation were determined by western blot analysis using
antibodies specific for phoshorylated ERK1/2 (Cell Signaling Technology, Inc.) and total
ERK1/2 (Upstate) as described (Vart et al., 2007). Levels of phosphorylated and total
IRAK1 were determined using antibodies from Cell Signaling Technology, Inc. A
neutralizing antibody against the human IFNαRII was obtained from Merck.
Participants and TLR4 SNP Analysis
Blood samples were collected from HIV-1-infected individuals attending the St. Stephen's
Centre at the Chelsea and Westminster Hospital. Sample collection, preparation, and DNA
extraction was carried out under ethical approval of the Riverside Research Ethics
Committee, and all participants gave informed consent. Genomic DNA was extracted from
5×106 peripheral blood mononuclear cells using the Nucleon Genomic DNA Extraction Kit
(Tepnel Life Sciences) according to the manufacturer's instructions. DNA was resuspended
in RNase/DNase free water (Sigma) to a final concentration of 50 ng/μl and stored at −20°C
until required. TLR4 SNPs were assessed by pyrosequencing (Biotage, UK). Primer
sequences were designed using Pyrosequencing Assay Design Software (Biotage) and were
as follows: Forward PCR primer GACGATTAGCATACTTAGACTACTACCTC, reverse
biotinylated PCR primer AGCCCAAGAAGTTTGAACTCAT, Asp299Gly sequencing
primer ATACTTAGACTACTACCTCG, and Ile399Thr sequencing primer
CAAAGTGATTTTGGGAC. The biotin-labeled PCR products were purified with
Steptavidin TM Sepharose Beads (GE Healthcare) using the Pyrosequencing Preparation
Station (Biotage) and annealed to the sequencing primer at 80°C for 2 min. The samples
were then run according to the instrument (PyroMarkTMMD) parameters.
Lentiviral Expression of KSHV Genes
KSHV genes were cloned from the BC3 and BC1 PEL cell lines and were expressed using a
modified pSIN-MCS lentiviral vector as described (Vart et al., 2007). The number of
lentiviral copies per cell was determined by qPCR and viral gene expression was confirmed
by RT-PCR. All experiments shown were performed 3 days postlentivirus infection.
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qRTPCR and qPCR
Genomic DNA and total RNA were extracted using the QIAamp DNA mini and RNEasy
mini kits, respectively (both from QIAGEN). TLR4, TLR9, TNF-α, IL1-β, IL-6, LANA,
ORF50, vIRF-1, vGPCR, and ORF26 mRNA levels were quantified by qRTPCR using the
SYBR Green Master Mix (Applied Biosystems, ABI Prism 7700). Optimized forward and
reverse primers for these genes and GAPDH (house-keeping reference gene) were used at
final concentration of 300 nM. For ERK1, ERK2, and IFN-β qRTPCR, commercially
available primers were used (Applied Biosytems). Cell-associated and plasma KSHV loads
were determined by qPCR as described (Bourboulia et al., 2004).
TNF-α ELISA
TNF-α levels in supernatants from LPS stimulated LEC were determined using a
commercially available ELISA (R&D Systems). TNF-α was not detectable in supernatants
of nonstimulated cells.
RNA Interference
LEC were seeded in 6-well plates 1 day prior to transfection with ERK1-, ERK2-, or TLR4-
targeting or nontargeting (scramble) siRNA (OnTargetPlus SmartPool from Dharmacon).
The concentration of siRNA was 100 nM, and cells were transfected using oligofectamine
reagent (Invitrogen). Cells were infected with KSHV 48 hr post siRNA transfection.
Pharmacologic Inhibitions
We used the chemical inhibitors BAY11-7082 (NF-κB inhibitor, 5 μM), JNK inhibitor II
(25 μM), SB202190 (p38/MAPK inhibitor, 10 μM), PD98059 (MEK inhibitor, 10 μM),
UO126 (MEK inhibitor, 10 μM), and LY294002 (PI3K inhibitor, 5 μM), all from
Calbiochem. For LEC and KLEC at 72 hr p.i., and LEC infected with lentivirus, the
inhibitors were added to the cells for 6 hr, apart from BAY11-7082 and LY294002, which
were added for 2 hr and 4 hr, respectively. For LEC and KLEC at 6 hr p.i., all inhibitors
were added to the cells for 2 hr prior to infection and removed during infection. Polymyxin
B, N-acetylcysteine, and ascorbic acid (all from Sigma) were used at 10 mg/ml, 2.5 mM,
and 1 mM concentrations, respectively. Cell viability was not affected by any of the
inhibitors in the above conditions (not shown).
TLR Promoter Analysis
The promoters (1 kB upstream the transcription start site) of human TLR4 and TLR9 were
analyzed using DiAlign TF with incorporated MatInspector software.
Statistical Analysis
All experiments were performed in four to six independent replicates, and error bars
correspond to standard deviation from the mean. Statistical significance (P values) was
determined with a two-sided unpaired Student's t test. Statistical analysis of GEM was
performed as described using a moderated t statistic and a false discovery rate correction
(Lagos et al., 2007; Wang et al., 2004). Statistical significance of the frequency of the TLR4
SNPs among HIV-1-infected individuals was determined using the Fischer Exact Probability
Test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. KSHV Suppresses TLR4 Expression
(A) Heatmap of TLR expression in LEC and KSHV-infected LEC (KLEC; 72 hr p.i.), based
on GEM profiling. Rows correspond to TLR probe sets. Red and blue denote high and low
expression respectively, the color scale indicating units of standard deviation from the mean.
(B) TLR4 and TLR9 mRNA levels in LEC (gray bars) and KLEC (black bars) 72 hr p.i.
(C) Surface TLR4 expression in LEC and GFP-expressing KLEC (72 hr p.i.).
(D) Time course of TLR4 mRNA levels in LEC (gray bars) and KLEC (black bars). For
each time point, mRNA levels are normalized to LEC TLR4 mRNA levels.
(E) TLR4 mRNA levels in LEC infected with UV-inactivated KSHV normalized to KLEC
TLR4 mRNA at 6 hr and 72 hr p.i. P value between UV-inactivated samples and KLEC is
shown.
(F) TLR4 mRNA levels in relation to percentage of GFP-expressing KLEC (24 hr p.i.).
Values normalized to LEC and P values shown.
(G) Levels of phosphorylated and total IRAK1 (p-IRAK1 and t-IRAK1, respectively)
following stimulation of LEC and KLEC (72 hr p.i.) with 100ng/ml LPS/1 μg/ml sCD14 for
the indicated time. GAPDH levels are shown as loading controls. Note that the increase of
the t-IRAK1 signal in LEC following LPS stimulation represents an increase in the activated
form of the protein rather than an increase in the total protein levels (Hatao et al., 2004).
(H) Levels of secreted TNF-α following stimulation of LEC (gray bars) and KLEC (black
bars; 72 hr p.i.) with LPS/sCD14 for 6 hr and 24 hr. For (B)–(D) and (H), P values between
KLEC and LEC, samples are shown. In all panels, error bars represent standard deviation.
Lagos et al. Page 14
Cell Host Microbe. Author manuscript; available in PMC 2009 June 18.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 2. Increased Susceptibility of Cells Lacking TLR4 to KSHV Infection
(A) mRNA levels of KSHV-encoded LANA-1 and ORF50 transcripts after KSHV infection
(48 hr p.i.) of peritoneal macrophages from C57BL10/ScSnJ mice (wild-type, white bars)
and C57BL10/ScNJ mice (Tlr4−/−, gray bars). Levels normalized to average gene
expression in KSHV-infected C57BL10/ScSnJ macrophages. P values indicate statistical
significance of changes between C57BL10/ScNJ and C57BL10/ScSnJ macrophages.
(B) LANA-1 mRNA levels (white bars) in KLEC (48 hr p.i.). LEC were transfected with
nontargeting siRNA (KLEC scramble) or TLR4-targeting siRNA (KLEC-siTLR4) 48 hr
before KSHV infection. TLR4 surface expression (histograms; TLR4 geometrical mean
fluorescence shown) and mRNA levels (black bars) were determined 48 hr post siRNA
transfection. mRNA levels are normalized to KLEC-scramble levels.
(C) TNF-α, IL1-β, IL-6, and IFN-β mRNA levels 6 hr after KSHV infection of KLEC
scramble (black bars) or KLEC-siTLR4 (gray bars). Levels are normalized to KLEC
scramble.
(D) As in (C), but after exposure of LEC to UV-inactivated KSHV. In (B)–(D), P values
indicate statistical significance of changes between mRNA levels in KLEC scramble and
KLEC-siTLR4. In all panels, error bars represent standard deviation.
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Figure 3. TLR4 Activation by LPS Protects LEC from KSHV Infection
(A) Percentage of GFP-expressing cells in KLEC, KLEC pretreated with sCD14 (1 μg/ml),
and KLEC pretreated with sCD14 (1 μg/ml) and LPS (100 ng/ml).
(B) Average number of KSHV genomes per GFP-expressing cell. Cells were pretreated as
described in (A).
(C) mRNA levels of KSHV latent, immediate lytic, and late lytic genes (LANA, ORF50,
and ORF26, respectively) in KLEC pretreated with sCD14 (gray bars) or sCD14 and LPS
(black). Levels are normalized to sCD14 pretreated KLEC. In (A)–(C), P values between
KLEC pretreated with sDC14 and sCD14/LPS are shown, and experiments are performed 72
hr p.i.
(D) IFN-β expression in LEC treated with PBS (black bars) or 1 μg/ml sCD14 (gray bars)
and varying amounts of LPS (x axis) for 6 hr. Ct values (y axis) indicate cycle number when
PCR products become detectable. Samples are normalized for GAPDH Ct. P values between
PBS/LPS- and sCD14/LPS-treated LEC for each LPS concentration are shown.
(E) ORF50 mRNA levels in KLEC and in KLEC pre-treated with sCD14 and LPS or IFN-β
(1000U/ml) in the presence of an IFNaRII neutralizing antibody (white bars) or an isotype
control (gray bars). IFN-β treatment was used to assess the neutralizing efficiency of the
antibody. P values indicate significant changes compared with to KLEC control. In all
panels, error bars represent standard deviation.
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Figure 4. Increased Susceptibility of LEC-TLR4A/G to KSHV Infection
(A) TLR4 expression in LEC-TLR4A/A (wild-type TLR4) and LEC-TLR4A/G (heterozygous
mutation in TLR4 gene). Inserts show the corresponding pyrograms showing a 50% loss of
the fourth peak (corresponding to A) and 50% increase of the third peak (corresponding to a
G) in the mutant cells. Bar graph shows mRNA levels of TLR4 and TLR9 in LEC-TLR4A/A
(gray bars) and LEC-TLR4A/G (black bars).
(B) mRNA levels of inflammatory cytokines and IFN-β in LEC-TLR4A/A (gray bars) and
LEC-TLR4A/G (black bars) 6 hr poststimulation with LPS/sCD14. P values indicate
significant changes compared to LEC-TLR4A/A. mRNA levels are corrected for background
transcription (in nonstimulated LEC).
(C) Representative dot plot of KSHV infected LEC-TLR4A/A and LEC-TLR4A/G. Numbers
correspond to percentage of infected cells.
(D) KSHV gene expression in KLEC-TLR4A/A (gray bars) and KLEC-TLR4A/G (black
bars) 72 hr p.i. P values indicate significant changes compared to KLEC-TLR4A/A. In all
panels, error bars represent standard deviation.
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Figure 5. Association of TLR4 SNP with MCD
(A) TLR4 SNP map of 109 HIV-1-infected individuals. PN, patient number, DS, disease
status (black, MCD and KS; dark gray, MCD; light gray, KS; white, other), A/G,
Asp299Gly, and C/T, Ile399Thr. Red and green boxes indicate presence of the
corresponding SNP.
(B) Clinical characteristics and SNP incidence in the studied cohort. P values are calculated
with Fischer Exact Probability Test.
(C) Box plot of plasma KSHV load at time of diagnosis in individuals with MCD (with or
without KS) and KS only (available for 16 participants with KS only). Boxes indicate the
lower and upper quartiles, and the line indicates the median viral load for each group. The
ends of the lines outside the boxes indicate minimum and maximum loads, whereas circles
represent outliers. Median and range of each group are also shown on top of each box. P
value between the two groups is also shown.
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Figure 6. vIRF1 and vGPCR Contribute to the Downregulation of TLR4
(A) TLR4 mRNA and surface expression (geometrical mean fluorescence) levels in LEC
expressing increasing amounts of vIRF1 (shown as average number of lentiviral copies per
cell, cc) and empty lentiviral vector (pSIN). Levels normalized to LEC-pSIN.
(B) TLR4 mRNA and surface expression levels in LEC expressing pSIN, vIRF1, vGPCR,
and vIRF1 and vGPCR.
(C) Fold mRNA TNF-α induction and TNF-α secreted levels in LEC-expressing vIRF1 and
vGPCR (black bars) or pSIN (gray bars) after stimulation with LPS/sCD14 and fold mRNA
TNF-α induction after stimulation with CpG DNA. P values between stimulated LEC-pSIN
and LEC-vIRF1/vGPCR are shown. For all panels, experiments were performed 72 hr p.i. In
all panels, error bars represent standard deviation.
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Figure 7. ERK Activation Contributes to TLR4 Downregulation in KLEC
(A) TLR4 mRNA levels in LEC-pSIN (black bar) and LEC-expressing vGPCR (gray bars)
after treatment with the chemical inhibitors LY294002 (LY), BAY11-7082 (BAY),
SB202190 (SB), JNK inhibitor II (JNK), PD98059 (PD), and UO126 (UO). Controls were
treated with 0.1% DMSO.
(B) TLR4 mRNA levels in LEC-pSIN (black bar) and LEC-vGPCR (gray bars) after
treatment with DMSO, 1 μM and 10 μM of UO126. Inset shows protein levels of
phosphorylated and total ERK in LEC-pSIN and LEC-vGPCR. For (A) and (B), levels are
normalized to LEC-pSIN/0.1% DMSO.
(C) TLR4 expression in LEC-pSIN (black bars) and LEC-vGPCR (72 hr p.i., gray bars).
LEC were transfected with nontargeting siRNA (scramble) or siRNAs targeting ERK1 and
ERK2 (siERK) 48 hr before infection with pSIN or vGPCR lentivirus. Inset shows levels of
ERK1 (top band) and ERK2 (bottom band) in scramble and siERK LEC (48 hr
posttransfection). Significant P values between LEC-pSIN and LEC-vGPCR are shown. Bar
graph shows levels of ERK1 and ERK2 in LEC-siERK compared to LEC-scramble 48 hr
posttransfection.
(D) TLR4 expression in LEC (black bars) and KLEC (72 hr p.i., gray bars) after treatment of
cells with DMSO, SB202190, JNK inhibitor II, UO126, PD98059, or LY294002. P values
indicate statistical significance of changes between KLEC-DMSO and KLEC-UO or KLEC-
PD. Inset shows protein levels of phosphorylated and total ERK in LEC-DMSO, KLEC-
DMSO, and KLEC treated with UO126 MEK-inhibitor. P values indicate statistically
significant changes between LEC-DMSO and KLEC samples.
(E) TLR4 expression in LEC (black bars) and KLEC (6 hr p.i., gray bars) after treatment
with DMSO (control for chemical inhibitors) or media (control for antioxidants), N-acetyl-
cysteine and ascorbic acid (anti-oxidants), LY294002, and UO126. TLR9 mRNA levels in
LEC-DMSO, KLEC-DMSO, and KLEC treated with UO126 (6 hr p.i.).
(F) TLR4 expression in LEC (black bars) and KLEC (6 hr p.i., gray bars). Cells were
transfected with nontargeting siRNA (scramble) or siRNAs targeting ERK1 and ERK2
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(siERK) 48 hr before infection with KSHV. P values indicate significant changes between
LEC and KLEC. In all panels, error bars represent standard deviation.
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